May 21, 2025 12:50 PM EDTUpdated 01:40 PM

FDA adcomm narrowly votes against UroGen’s bladder cancer drug, calls for RCTs

Zachary Brennan

Senior Editor

The FDA’s Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen Pharma’s mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA adcomm narrowly votes against UroGen’s bladder cancer drug, calls for RCTs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Hinge Health is going public on Thursday at a $3B valuation

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

FDA asks Covid vaccine makers to add more myocarditis data to labels

Updated: Eikon Therapeutics cuts staff for the second time in less than two years

Altos Labs buys anti-aging startup Dorian Therapeutics

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

FDA ad­comm nar­row­ly votes against Uro­Gen’s blad­der can­cer drug, calls for RCTs

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA adcomm narrowly votes against UroGen’s bladder cancer drug, calls for RCTs